Detalhe da pesquisa
1.
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy.
Nature
; 570(7759): 112-116, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31092922
2.
Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.
Oncologist
; 26(6): 514-522, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33655682
3.
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis.
Nat Med
; 30(5): 1349-1362, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38724705
4.
Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor.
bioRxiv
; 2023 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37790460
5.
Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Arthritis Rheumatol
; 74(3): 527-540, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34397169
6.
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer.
J Immunother Cancer
; 9(9)2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34544895
7.
Using electronic visits (E-visits) to achieve goal serum urate levels in patients with gout in a rheumatology practice: A pilot study.
Semin Arthritis Rheum
; 50(6): 1382-1386, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359694
8.
Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
Semin Arthritis Rheum
; 48(6): 1127-1132, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30409415
9.
Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment.
Arthritis Res Ther
; 17: 262, 2015 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26387933